Jun 2026 (Q2 FY26) — Aug 5, 2026
Vir Biotechnology Q2 FY26 — Strong Financials and Pipeline Advancement
Read the full callVir Biotechnology (VIR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Vir Biotechnology earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 239 | +19582.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 30.8 | +9785.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 80.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$10.21 +2.51% · +$0.25
Performance +76.6% 1Y
1Y: $5.78 on 17 Oct 2025 → $10.21. High $11.78 (5 Oct 2026), low $5.12 (6 Nov 2025).
- Previous close
- $9.96
- 52-week range
- $5.12 – $11.78
- One year
- +62.84%
Overview
- Symbol
- VIR
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Vir Biotechnology earnings calls (VIR)
Financials
What the filings say
Net profit, year on year: +172% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 12 | 3 | 1 | 0 | 64 | -0 | 239 |
| Expenses | 234 | 130 | 143 | 120 | 174 | 112 | 132 | 165 |
| Operating profit | -231 | -117 | -140 | -118 | -173 | -48 | -132 | 73 |
| Operating margin | −9718.7% | −946.7% | −4602.5% | −9754.3% | −72267.9% | −74.8% | 456172.4% | 30.8% |
| Other income | 18 | 12 | 19 | 8 | 10 | 5 | 7 | 7 |
| Profit before tax | -214 | -105 | -121 | -111 | -163 | -43 | -126 | 80 |
| Tax rate | −0.1% | 0.1% | −0.0% | −0.1% | −0.1% | 0.3% | −0.1% | 0.2% |
| Net profit | -214 | -105 | -121 | -111 | -163 | -43 | -126 | 80 |
| EPS ($ per share) | -1.56 | — | -0.88 | -0.80 | -1.17 | — | -0.85 | 0.48 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -194 | -369 | -667 | -139 | 377 | -238 | -760 | -1,198 |
| Total liabilities | 62 | 88 | 202 | 522 | 724 | 329 | 248 | 238 |
| Fixed assets | 12 | 16 | 18 | 43 | 106 | 96 | 63 | 56 |
| Investments | 51 | 274 | 300 | 217 | 1,522 | 1,271 | 678 | 229 |
| Total assets | 192 | 512 | 919 | 1,954 | 2,802 | 1,919 | 1,399 | 1,003 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -94 | -130 | -191 | -48 | 1,663 | -779 | -446 | -392 |
| Cash from investing | -60 | -256 | -10 | -141 | -1,193 | 165 | 499 | 310 |
| Cash from financing | 25 | 449 | 529 | 100 | 35 | 7 | 4 | 4 |
| Net cash flow | -130 | 63 | 329 | -88 | 505 | -607 | 57 | -78 |
| Capital expenditure | -8 | -9 | -7 | -22 | -68 | -22 | -7 | -5 |
| Free cash flow | -102 | -139 | -197 | -69 | 1,595 | -800 | -454 | -397 |
Insider filings
63 filings between Oct 20, 2025 and Aug 11, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$13.00M
43 sales by 8 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 13
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
Also filed: 6 other filings.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| SVF Endurance (Cayman) Ltd | — | $9.98M | Dec 1, 2025 |
| SATO VICKI L | — | $1.60M | May 1, 2026 |
| De Backer Marianne | — | $947.0K | Apr 6, 2026 |
| de Verneuil Vanina | — | $217.7K | Feb 25, 2026 |
| Sabatini Brent | — | $113.1K | Jun 1, 2026 |
| O'Byrne Jason | — | $68.9K | Feb 24, 2026 |
| Eisner Mark | — | $49.5K | Feb 25, 2026 |
| Napolitano Janet | — | $30.2K | Jun 1, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 11, 2026 | MORE ROBERT J Director | Other | 8,000 | $0 |
| Aug 11, 2026 | MORE ROBERT J Director | Other | 8,000 | $0 |
| Jun 9, 2026 | COUGHLIN TIMOTHY Director | Award | 8,000 | $0 |
| Jun 9, 2026 | COUGHLIN TIMOTHY Director | Award | 8,000 | $0 |
| Jun 1, 2026 | Napolitano Janet Director | Sale 10b5-1 plan | 3,200 | $30.2K |
| Jun 1, 2026 | Sabatini Brent SVP, Chief Accounting Officer | Sale 10b5-1 plan | 379 | $3.6K |
| May 27, 2026 | BISCHOFBERGER NORBERT W Director | Award | 8,000 | $0 |
| May 27, 2026 | Sigal Charles Elliott Director | Award | 8,000 | $0 |
| May 27, 2026 | Napolitano Janet Director | Award | 8,000 | $0 |
| May 27, 2026 | MORE ROBERT J Director | Award | 8,000 | $0 |
| May 27, 2026 | Hatfield Jeffrey S. Director | Award | 8,000 | $0 |
| May 27, 2026 | Farid Ramy Director | Award | 8,000 | $0 |
| May 1, 2026 | SATO VICKI L Director | Sale 10b5-1 plan | 22,000 | $221.0K |
| Apr 29, 2026 | De Backer Marianne President and CEO | Other | 233,532 | $0 |
| Apr 29, 2026 | De Backer Marianne President and CEO | Other | 233,532 | $0 |
| Apr 6, 2026 | De Backer Marianne President and CEO | Sale 10b5-1 plan | 72,559 | $664.4K |
| Apr 1, 2026 | SATO VICKI L Director | Sale 10b5-1 plan | 22,000 | $199.6K |
| Mar 23, 2026 | Sabatini Brent SVP, Chief Accounting Officer | Sale 10b5-1 plan | 7,711 | $70.3K |
| Mar 20, 2026 | O'Byrne Jason EVP & Chief Financial Officer | Other | 2,500 | $0 |
| Mar 20, 2026 | O'Byrne Jason EVP & Chief Financial Officer | Other | 2,500 | $0 |
| Mar 2, 2026 | SATO VICKI L Director | Sale 10b5-1 plan | 200 | $2.0K |
| Mar 2, 2026 | SATO VICKI L Director | Sale 10b5-1 plan | 21,800 | $207.2K |
| Feb 25, 2026 | Eisner Mark EVP and Chief Medical Officer | Sale 10b5-1 plan | 1,889 | $18.5K |
| Feb 25, 2026 | de Verneuil Vanina EVP, General Counsel, Corp Sec | Sale 10b5-1 plan | 13,700 | $134.5K |
| Feb 24, 2026 | SATO VICKI L Director | Option exercise 10b5-1 plan | 42,377 | $62.9K |
| Feb 24, 2026 | Sabatini Brent SVP, Chief Accounting Officer | Sale 10b5-1 plan | 1,430 | $13.6K |
| Feb 24, 2026 | O'Byrne Jason EVP & Chief Financial Officer | Sale 10b5-1 plan | 1,634 | $15.6K |
| Feb 24, 2026 | de Verneuil Vanina EVP, General Counsel, Corp Sec | Sale 10b5-1 plan | 3,117 | $29.7K |
| Feb 24, 2026 | Eisner Mark EVP and Chief Medical Officer | Sale 10b5-1 plan | 1,616 | $15.4K |
| Feb 24, 2026 | SATO VICKI L Director | Sale 10b5-1 plan | 42,177 | $411.3K |
| Feb 24, 2026 | SATO VICKI L Director | Sale 10b5-1 plan | 200 | $2.1K |
| Feb 24, 2026 | De Backer Marianne Chief Executive Officer | Sale 10b5-1 plan | 14,762 | $140.7K |
| Feb 23, 2026 | Sabatini Brent SVP, Chief Accounting Officer | Sale 10b5-1 plan | 1,829 | $13.6K |
| Feb 23, 2026 | O'Byrne Jason EVP & Chief Financial Officer | Sale 10b5-1 plan | 2,089 | $15.6K |
| Feb 23, 2026 | Eisner Mark EVP and Chief Medical Officer | Sale 10b5-1 plan | 2,089 | $15.6K |
| Feb 23, 2026 | De Backer Marianne Chief Executive Officer | Sale 10b5-1 plan | 19,039 | $141.9K |
| Feb 23, 2026 | de Verneuil Vanina EVP, General Counsel, Corp Sec | Sale 10b5-1 plan | 4,445 | $33.1K |
| Feb 22, 2026 | De Backer Marianne Chief Executive Officer | Award 10b5-1 plan | 285,000 | $0 |
| Feb 22, 2026 | de Verneuil Vanina EVP, General Counsel, Corp Sec | Award 10b5-1 plan | 55,000 | $0 |
| Feb 22, 2026 | Sabatini Brent SVP, Chief Accounting Officer | Award 10b5-1 plan | 25,000 | $0 |
| Feb 22, 2026 | O'Byrne Jason EVP & Chief Financial Officer | Award 10b5-1 plan | 55,000 | $0 |
| Feb 22, 2026 | Eisner Mark EVP and Chief Medical Officer | Award 10b5-1 plan | 55,000 | $0 |
| Feb 13, 2026 | Sabatini Brent SVP, Chief Accounting Officer | Sale 10b5-1 plan | 1,530 | $11.9K |
| Feb 2, 2026 | SATO VICKI L Director | Sale 10b5-1 plan | 22,000 | $169.7K |
| Jan 2, 2026 | SATO VICKI L Director | Sale 10b5-1 plan | 22,000 | $130.4K |
| Dec 1, 2025 | SVF Endurance (Cayman) Ltd 10% owner | Sale 10b5-1 plan | 191,854 | $1.15M |
| Dec 1, 2025 | SATO VICKI L Director | Sale 10b5-1 plan | 22,000 | $132.1K |
| Nov 28, 2025 | SVF Endurance (Cayman) Ltd 10% owner | Sale 10b5-1 plan | 61,493 | $396.0K |
| Nov 26, 2025 | SVF Endurance (Cayman) Ltd 10% owner | Sale 10b5-1 plan | 127,938 | $817.7K |
| Nov 25, 2025 | SVF Endurance (Cayman) Ltd 10% owner | Sale 10b5-1 plan | 235,971 | $1.51M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Vir Biotechnology, Inc.
Free account. Everything above stays public.
Write why you follow Vir Biotechnology, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading